CORBIN P. ROUDEBUSH, M.D.; KATHLEEN E. HOYE, B.S.; LESLIE J. DeGROOT, M.D.
To minimize the high rate of residual thyrotoxicosis encountered in low-dose 131I therapy of Graves' disease, we have treated 62 patients with a low-dose 131I protocol that includes a compensation for thyroid size. Dose varied between 40 µCi retained/g for glands of normal size to 100 µCi/g for glands of 100 g or greater. Mean dose was 51.9 µCi/g. At 1 year after therapy, 66.1% of subjects were euthyroid, 9.7% hypothyroid, and 24.2% hyperthyroid, a significant improvement (P < 0.01) over our previous experience using 50 µCi/g independent of gland size. Several factors, other than 131I dose, which might influence the outcome of therapy, were investigated. Initial free thyroxine index observed before therapy was found to have prognostic significance. Hypothyroidism developed only in patients having an initial free thyroxine index of 22.5 or less (about 2.5 times the upper limit of normal in our laboratory).
ROUDEBUSH CP, HOYE KE, DeGROOT LJ. Compensated Low-Dose 131I Therapy of Graves' Disease. Ann Intern Med. ;87:441–443. doi: 10.7326/0003-4819-87-4-441
Download citation file:
Published: Ann Intern Med. 1977;87(4):441-443.
Endocrine and Metabolism, Thyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use